NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEM Russian patent published in 2024 - IPC C07D413/10 C07D413/14 C07D473/10 C07D487/10 A61K31/4245 A61K31/4439 A61K31/444 A61P25/00 A61P25/28 A61P29/00 A61P35/00 

FIELD: medicine; pharmaceutics.

SUBSTANCE: present invention relates to a novel compound of chemical formula I, or a pharmaceutically acceptable salt thereof, where is ; each of R₄ and R₅ is independently C1-C4 alkyl; Z₅ is N-R₆ or CH₂; R₆ is C1-C4 alkyl, -C(=O)-(C1-C4 alkyl), -C (=O)-O-(C1-C4 alkyl) or 4–6 membered heterocycloalkyl having one O; L₁ is -(C1-C2 alkylene)-; is C6-C12 aryl, 5–9 membered heteroaryl having at least one N, or ; each of R₂ and R₃ independently represents H, halogen, C6-C12 aryl, 5- or 6-member heteroaryl, having N or O, 5- or 6-member heterocycloalkyl, having N, 5- or 6-member heterocycloalkenyl having N, -C(=O)-O-(C1-C4 alkyl), -C(=O)-(C1-C4 alkyl), -NH-C(=O)-(C1-C4 alkyl), -NO₂ or -NH₂, at least one H of the above R₂ and R₃ can in each case be independently substituted with halogen or C1-C4 alkyl; and n, and m in each case is independently equal to 1 or 2. Invention also relates to a pharmaceutical composition containing a compound of chemical formula I, to a method for preventing or treating diseases mediated by histone deacetylase (HDAC), and to the use of a compound of chemical formula I for preventing or treating diseases mediated by HDAC.

EFFECT: enabling development of a selective inhibitor of HDAC6, which has a zinc-binding group, with improved bioavailability, which does not cause side effects, for treating cancer, inflammatory, autoimmune and neurological diseases, neurodegenerative disorders.

10 cl, 2 tbl, 38 ex